What does CUSIP 98420N105 represent in this 13F holders report?

CUSIP 98420N105 is the security identifier for XENE - Xenon Pharmaceuticals Inc. - Common Stock used to aggregate holder disclosures.

How many institutions held XENE - Xenon Pharmaceuticals Inc. - Common Stock in Q4 2021?

129 institutional investors reported XENE - Xenon Pharmaceuticals Inc. - Common Stock for Q4 2021. Use the holders table for investor-level position and value details.

Xenon Pharmaceuticals Inc. - Common Stock (XENE)

CUSIP: 98420N105

Q4 2021 13F Holders as of 31 Dec 2021

Type / Class: Equity / Common Stock
Shares outstanding: 76,851,274
Total 13F shares: 47,689,350
Share change: +13,210,129
Total reported value: $1,489,826,062
Put/Call ratio: 68%
Price per share: $31.24
Number of holders: 129
Value change: +$453,547,589
Number of buys: 80
Number of sells: 48

Quarterly Holders Quick Answers

What is CUSIP 98420N105?
CUSIP 98420N105 identifies XENE - Xenon Pharmaceuticals Inc. - Common Stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q1 2022
Previous quarter: Q3 2021

Recent filing periods for CUSIP 98420N105:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of XENE - Xenon Pharmaceuticals Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Avoro Capital Advisors LLC	13F	Company	4.7%	3,650,000	$55,772,000	—	30 Sep 2021	13F
FMR LLC	13F	Company	4%	3,056,756	$46,707,000	—	30 Sep 2021	13F
PERCEPTIVE ADVISORS LLC	13F	Company	2.6%	2,022,051	$30,897,000	—	30 Sep 2021	13F
BVF INC/IL	13F	Company	2%	1,571,778	$24,017,000	—	30 Sep 2021	13F
DRIEHAUS CAPITAL MANAGEMENT LLC	13F	Company	2%	1,511,543	$23,096,000	—	30 Sep 2021	13F
ADAGE CAPITAL PARTNERS GP, L.L.C.	13F	Company	1.5%	1,175,000	$17,954,000	—	30 Sep 2021	13F
SUVRETTA CAPITAL MANAGEMENT, LLC	13F	Company	1.5%	1,158,961	$17,709,000	—	30 Sep 2021	13F
Point72 Asset Management, L.P.	13F	Company	1.4%	1,077,800	$16,469,000	—	30 Sep 2021	13F
Capital International Investors	13F	Company	1.4%	1,055,726	$16,131,000	—	30 Sep 2021	13F
NEA Management Company, LLC	13F	Company	1.3%	992,107	$15,159,000	—	30 Sep 2021	13F
Capital World Investors	13F	Company	1.3%	963,500	$14,722,000	—	30 Sep 2021	13F
Bank of New York Mellon Corp	13F	Company	1.2%	934,643	$14,282,000	—	30 Sep 2021	13F
Boxer Capital, LLC	13F	Company	1.1%	857,000	$13,095,000	—	30 Sep 2021	13F
CITADEL ADVISORS LLC	13F	Company	1.1%	841,216	$12,854,000	—	30 Sep 2021	13F
Ghost Tree Capital, LLC	13F	Company	1%	790,000	$12,071,000	—	30 Sep 2021	13F
BAKER BROS. ADVISORS LP	13F	Company	0.98%	751,639	$11,485,000	—	30 Sep 2021	13F
S.c.a. Candriam	13F	Individual	0.93%	715,722	$10,936,000	—	30 Sep 2021	13F
GREAT POINT PARTNERS LLC	13F	Company	0.91%	700,000	$10,696,000	—	30 Sep 2021	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.81%	619,077	$9,459,000	—	30 Sep 2021	13F
Rock Springs Capital Management LP	13F	Company	0.76%	583,100	$8,910,000	—	30 Sep 2021	13F
Commodore Capital LP	13F	Company	0.75%	579,432	$8,854,000	—	30 Sep 2021	13F
ORBIMED ADVISORS LLC	13F	Company	0.62%	477,000	$7,289,000	—	30 Sep 2021	13F
BlackRock Finance, Inc.	13F	Company	0.58%	443,052	$6,771,000	—	30 Sep 2021	13F
ACUTA CAPITAL PARTNERS, LLC	13F	Company	0.54%	417,409	$6,378,000	—	30 Sep 2021	13F
DAFNA Capital Management LLC	13F	Company	0.53%	406,535	$6,212,000	—	30 Sep 2021	13F
LORD, ABBETT & CO. LLC	13F	Company	0.49%	378,358	$5,781,000	—	30 Sep 2021	13F
Ikarian Capital, LLC	13F	Company	0.49%	377,438	$5,767,000	—	30 Sep 2021	13F
SPHERA FUNDS MANAGEMENT LTD.	13F	Company	0.49%	373,510	$5,707,000	—	30 Sep 2021	13F
Marshall Wace North America L.P.	13F	Company	0.44%	338,301	$5,169,000	—	30 Sep 2021	13F
Parkman Healthcare Partners LLC	13F	Company	0.4%	311,207	$4,755,000	—	30 Sep 2021	13F
Tri Locum Partners LP	13F	Company	0.34%	264,134	$4,036,000	—	30 Sep 2021	13F
ALLIANCEBERNSTEIN L.P.	13F	Company	0.34%	263,103	$4,020,000	—	30 Sep 2021	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.31%	236,219	$3,609,000	—	30 Sep 2021	13F
Altium Capital Management LLC	13F	Company	0.28%	216,000	$3,300,000	—	30 Sep 2021	13F
Soleus Capital Management, L.P.	13F	Company	0.28%	215,697	$3,296,000	—	30 Sep 2021	13F
Michael R. Hayden	3/4/5	Director	— mixed-class rows	332,685 mixed-class rows	$3,178,448	—	03 Jun 2021	3/4/5
Woodline Partners LP	13F	Company	0.26%	199,984	$3,056,000	—	30 Sep 2021	13F
Nan Fung Group Holdings Ltd	13F	Company	0.26%	197,880	$3,024,000	—	30 Sep 2021	13F
Monashee Investment Management LLC	13F	Company	0.23%	180,000	$2,750,000	—	30 Sep 2021	13F
TWO SIGMA ADVISERS, LP	13F	Company	0.23%	175,800	$2,686,000	—	30 Sep 2021	13F
ALTRINSIC GLOBAL ADVISORS LLC	13F	Company	0.22%	170,000	$2,598,000	—	30 Sep 2021	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	0.22%	169,676	$2,593,000	—	30 Sep 2021	13F
Tekla Capital Management LLC	13F	Company	0.22%	169,030	$2,583,000	—	30 Sep 2021	13F
AXA S.A.	13F	Company	0.21%	159,643	$2,439,000	—	30 Sep 2021	13F
DIMENSIONAL FUND ADVISORS LP	13F	Company	0.2%	151,197	$2,310,000	—	30 Sep 2021	13F
D. E. Shaw & Co., Inc.	13F	Company	0.19%	148,879	$2,275,000	—	30 Sep 2021	13F
STATE STREET CORP	13F	Company	0.19%	147,447	$2,253,000	—	30 Sep 2021	13F
Schonfeld Strategic Advisors LLC	13F	Company	0.16%	120,121	$1,836,000	—	30 Sep 2021	13F
VANGUARD GROUP INC	13F	Company	0.14%	107,192	$1,638,000	—	30 Sep 2021	13F
FRED ALGER MANAGEMENT, LLC	13F	Company	0.14%	105,989	$1,620,000	—	30 Sep 2021	13F

Institutional Holders of Xenon Pharmaceuticals Inc. - Common Stock (XENE) as of Q4 2021

As of 31 Dec 2021, Xenon Pharmaceuticals Inc. - Common Stock (XENE) was held by 129 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 47,689,350 shares. The largest 10 holders included Avoro Capital Advisors LLC, FMR LLC, BVF INC/IL, DRIEHAUS CAPITAL MANAGEMENT LLC, Point72 Asset Management, L.P., PERCEPTIVE ADVISORS LLC, Capital World Investors, LORD, ABBETT & CO. LLC, Polar Capital Holdings Plc, and CITADEL ADVISORS LLC. This page lists 130 institutional shareholders reporting positions in this security for the Q4 2021 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q4 2021 vs Q3 2021 Across Filers

Q3 2021 holders

113

Q4 2021 holders

129

Holder diff

Investor	Q3 2021 Shares	Q4 2021 Shares	Share Diff	Share Chg %	Q3 2021 Value $	Q4 2021 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.